[How should hormone therapy for castration-resistant prostate cancer be continued?]

Spahn, M; Krebs, M (2012). [How should hormone therapy for castration-resistant prostate cancer be continued?]. Urologe, 51(1), pp. 15-19. Berlin: Springer 10.1007/s00120-011-2738-9

[img]
Preview
Text
s00120-011-2738-9.pdf - Published Version
Available under License Publisher holds Copyright.

Download (292kB) | Preview

After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but still androgen-sensitive tumor growth. Our understanding and the treatment of such castration-resistant prostate cancer has changed markedly. The introduction of new drugs like abiraterone and MDV3100 has shown that prostate cancer progression even in the"hormone-refractory" stage is driven by androgen receptor signaling. Based on this information the question of whether androgen deprivation therapy in castration-resistant prostate cancer should be continued or not is still of relevance. This review gives a critical overview of the literature and current guideline recommendations.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Spahn, Martin

ISSN:

0340-2592

Publisher:

Springer

Language:

German

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:38

Last Modified:

05 Dec 2022 14:12

Publisher DOI:

10.1007/s00120-011-2738-9

PubMed ID:

22258371

Web of Science ID:

000300320700003

BORIS DOI:

10.48350/15466

URI:

https://boris.unibe.ch/id/eprint/15466 (FactScience: 222813)

Actions (login required)

Edit item Edit item
Provide Feedback